secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2026-07-27T13:08:03+00:00
Accession:  0001193125-26-316995
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta names Michael Severino CEO effective July 28; Ingram retires
--------------------------------------------------------------------

- Michael Severino appointed CEO effective July 28, 2026; succeeds Doug Ingram who retires.
- Severino receives $1.18M base salary, 110% target bonus, and $35M sign-on equity grant.
- Ingram to serve as consultant through Dec 2026 at $15k/month consulting fee.
- Severino previously CEO of Tessera Therapeutics and Vice Chairman/President at AbbVie.
- Severino also appointed to Sarepta's Board of Directors as Class I director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/d101719d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer